DAPTOMYCIN FOR INJECTION 500 MG — DIN 02490838
DAPTOMYCIN : 500 MG · SANDOZ CANADA INCORPORATED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is DAPTOMYCIN FOR INJECTION?
DAPTOMYCIN FOR INJECTION 500 MG contains DAPTOMYCIN : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02490838, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 27-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DAPTOMYCIN FOR INJECTION used for?
Daptomycin for Injection (daptomycin) is indicated for complicated skin and skin structure infections (cSSSI) caused by susceptible strains of Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes and Streptococcus agalactiae. It is also indicated for Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains in adults and pediatric patients (aged 1 to 17 years).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Daptomycin cost around the world?
Daptomycin is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 1 | 21 | USD███.██ |
| Greece | producer price (ex-factory) | 16 | 16 | EUR███.██ |
| Saudi Arabia | public | 6 | 8 | SAR███.██ |
| South Africa | single exit price | 8 | 8 | ZAR███.██ |
| Bahrain | retail (max) | 5 | 5 | BHD███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 5 | NOK███.██ |
| United Arab Emirates | public | 2 | 3 | AED███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
69 pack listings across 44 brand entries and 8 price bases, refreshed 07 Sep 2026. Ranges span every Daptomycin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Daptomycin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Daptomycin, across 13 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CUBIST PHARMACEUTICALS LLC | 2 | 1 | CUBICIN, CUBICIN RF | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 2 | 1 | DAPTOMYCIN FOR INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | DAPTOMYCIN FOR INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 2 | 0 | DAPTOMYCIN FOR INJECTION | No marketed DIN |
| ACCORD HEALTHCARE INC | 1 | 0 | DAPTOMYCIN FOR INJECTION | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | DAPTOMYCIN FOR INJECTION RF | No marketed DIN |
| BAXTER CORPORATION | 1 | 0 | DAPTOMYCIN FOR INJECTION RF | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | DAPTOMYCIN FOR INJECTION RF | No marketed DIN |
| JUNO PHARMACEUTICALS CORP. | 1 | 0 | DAPTOMYCIN FOR INJECTION | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | DAPTOMYCIN FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Daptomycin |
|---|---|
| ATC code | J01XX09 |
| AHFS class | 84:80.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02490838 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2490838 |
| Brand name | DAPTOMYCIN FOR INJECTION |
| Generic / active ingredient | DAPTOMYCIN : 500 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | J01XX09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01XX |
| Current status | MARKETED |
| Status date | 27-Oct-2020 |
| Original market date | 2019-11-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Daptomycin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CUBICIN RF | 500 MG | POWDER FOR SOLUTION | CUBIST PHARMACEUTICALS LLC | MARKETED | 02465493 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02490463 |
| CUBICIN | 500 MG | POWDER FOR SOLUTION | CUBIST PHARMACEUTICALS LLC | DORMANT | 02299909 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED PRE MARKET | 02462117 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | 02511738 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | CANCELLED POST MARKET | 02494590 |
| DAPTOMYCIN FOR INJECTION | 350 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | 02460009 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | 02460017 |
| DAPTOMYCIN FOR INJECTION | 350 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | CANCELLED PRE MARKET | 02526743 |
| DAPTOMYCIN FOR INJECTION RF | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | APPROVED | 02541920 |
2 · Same class — other molecules in ATC J01XX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Linezolid | APO-LINEZOLID · JAMP LINEZOLID · LINEZOLID · LINEZOLID INJECTION · +6 more | 19 | 8 | Yes |
| Daptomycin | CUBICIN · CUBICIN RF · DAPTOMYCIN FOR INJECTION · DAPTOMYCIN FOR INJECTION RF | 13 | 3 | Yes |
| Fosfomycin | FOSFOMYCIN POWDER FOR ORAL SOLUTION · IVOZFO · JAMP-FOSFOMYCIN · MONUROL | 6 | 3 | Yes |
| Bacitracin | BACIJECT · BACITRACIN FOR INJECTION · BACITRACIN FOR INJECTION, USP · BACITRACIN USP | 5 | 1 | Yes |
| Lefamulin | XENLETA | 2 | 0 | Not in Canada |
| Methenamine | HIP REX TAB 1GM · MANDELAMINE | 2 | 0 | Not in Canada |
| Methenamine, Combinations | SAPROLEX TAB · URASAL GRANULES | 2 | 0 | Not in Canada |
| Tedizolid | SIVEXTRO | 2 | 0 | Not in Canada |
| Spectinomycin | TROBICIN INJ 400MG/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01XA | Dalbavancin · Telavancin · Vancomycin | 62 | 23 |
| J01XE | Nitrofurantoin | 24 | 9 |
| J01XB | Colistin · Polymyxin B | 6 | 4 |
| J01XD | Metronidazole | 7 | 2 |
| J01XC | Fusidic Acid | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DAPTOMYCIN FOR INJECTION called?
The same molecule, Daptomycin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DAPTOCIDAL | Latin | Saudi Arabia |
| Daptomycin Accord Healthcare | Latin | Norway |
| Daptomycin Accordpharma | Latin | Norway |
| Daptomycin Amarox | Latin | Saudi Arabia |
| CUBACT | Latin | South Africa |
| Cubicin | Latin | South Africa |
| CUBICIN RF | Latin | Bahrain |
| Cusyn | Latin | South Africa |
| DACI | Latin | Saudi Arabia |
| Dapicub | Latin | South Africa |
| DAPTOMRED | Latin | Bahrain |
| DAPTOMYCIN | Latin | Bahrain |
| DAPTOMYCIN BOS | Latin | Saudi Arabia |
| Daptomycin Equity | Latin | South Africa |
| Daptomycin hameln | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.